Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.

Item
http://www.wikidata.org/entity/Q36821054
Immunological and Translational Aspects of NK Cell-Based Antitumor ImmunotherapiesChimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor ImmunityRole of Natural Killer Cells in HIV-Associated Malignancies.Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Advances in immunotherapy for the treatment of glioblastoma.The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.Engineering Natural Killer Cells for Cancer Immunotherapy.Natural Killer Cells: Angels and Devils for Immunotherapy.Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.Current state and future prospects of immunotherapy for glioma.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.
P2860

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.

Item
http://www.wikidata.org/entity/Q36821054
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dual targeting of glioblastoma ...... titumor activity and survival.
@en
type
label
Dual targeting of glioblastoma ...... titumor activity and survival.
@en
prefLabel
Dual targeting of glioblastoma ...... titumor activity and survival.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Dual targeting of glioblastoma ...... titumor activity and survival.
@en
P2093
P2860
P304
P31
P356
10.1080/2162402X.2015.1119354
P433
P478
P577
P5875
P698
P932